Dr. Lorenzo Gianni - Oncologia Rimini
Dr. Lorenzo Gianni - Oncologia Rimini
Dr. Lorenzo Gianni - Oncologia Rimini
SHOW LESS
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
N0432:phase II trial of docetaxel with<br />
capecitabine and bevacizumab<br />
• OR: 49%; 95% CI 34%-<br />
64%<br />
– ER+ve: 61%<br />
– ER-ve: 23%<br />
• mDOR: 11.8 mesi<br />
• median OS 28.4 mesi<br />
• OS-1a 84%<br />
• PFS-1a 49%<br />
• 98% almeno AEs G3 e<br />
69% almeno G4 AEs<br />
Perez EA. Ann Oncol. 2010;21(2):269-74
Change language